Accueil>>Signaling Pathways>> Endocrinology and Hormones>> GnRH>>Cetrorelix Acetate (SB-075 acetate)

Cetrorelix Acetate (SB-075 acetate) (Synonyms: SB-75)

Catalog No.GC33467

L'acétate de cétrorélix (acétate SB-075) (acétate SB-75) est un puissant antagoniste des récepteurs de l'hormone de libération des gonadotrophines (GnRH) avec une CI50 de 1,21 nM.

Products are for research use only. Not for human use. We do not sell to patients.

Cetrorelix Acetate (SB-075 acetate) Chemical Structure

Cas No.: 145672-81-7

Taille Prix Stock Qté
1mg
50,00 $US
En stock
5mg
91,00 $US
En stock
10mg
151,00 $US
En stock
25mg
304,00 $US
En stock
50mg
441,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Cetrorelix Acetate is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM.

Cetrorelix Acetate inhibits growth of ES-2 cell line at 1000 ng/ml. Cetrorelix Acetate has comparable antiproliferative effects as GnRH-I agonists indicating that the dichotomy of GnRH-I agonists and antagonists might not apply to the GnRH-I system in cancer cells[2].

[1]. Beckers T et al. Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay. Anal Biochem. 1997 Aug 15;251(1):17-23. [2]. Gründker C et al. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol. 2003 Oct 7;1:65.

Avis

Review for Cetrorelix Acetate (SB-075 acetate)

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Cetrorelix Acetate (SB-075 acetate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.